Hansen, Aaron R.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 487

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Hilton, J., Gelmon, K., Bedard, P. L., Tu, D., Xu, H., Tinker, A. V., Goodwin, R., Laurie, S. A., Jonker, D., Hansen, A. R., et al. (2022) · Nature Communications

DNA and Nucleic Acid ChemistryPARP inhibition in cancer therapy

Cited by 155

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Spreafico, A., Heirali, A. A., Araujo, D. V., Tan, T. J., Oliva, M., Schneeberger, P. H. H., Chen, B., Wong, M. K., Stayner, L.-A., Hansen, A. R., et al. (2023) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 96

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 72

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 62

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

Fizazi, K., Clarke, N. W., De Santis, M., Uemura, H., Fay, A. P., Karadurmus, N., Kwiatkowski, M., Alvarez-Fernandez, C., Jiang, S., Sotelo, M., et al. (2026) · Annals of Oncology

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 55

LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)

Sartor, O., Jiang, D. M., Smoragiewicz, M., Zibelman, M., Flechon, A., El-Haddad, G., Abikhzer, G., Saad, F., Tutrone, R., Tagawa, S. T., et al. (2024) · Annals of Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 23

Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future

Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology

Prostate Cancer Treatment and ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 21

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

Ribnikar, D., Stukalin, I., Bedard, P. L., Hamilton, R. J., Jewett, M., Warde, P., Chung, P., Anson-Cartwright, L., Templeton, A. J., Amir, E., et al. (2020) · Current Oncology

Inflammatory Biomarkers in Disease PrognosisTesticular diseases and treatments

Cited by 15